id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-306826-vbfdxoc2	Solerte, Sebastiano Bruno	Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19	2020-06-06		.txt	text/plain	2251	112	41	CONCLUSIONS: The use of DPP4 inhibitors, such as gliptins, in patients with COVID-19 with, or even without, type 2 diabetes, may offer a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection. The novel beta-coronavirus 2019 (SARS-CoV-2) has recently emerged as a threat for human kind, causing severe respiratory syndrome , associated with other systemic complications (i.e., intestinal infections, renal and heart failure) and with a relative high mortality [1] . The co-expression of ACE2 and DPP4/CD26 as receptors of spike glycoproteins could hypothesize that different human coronaviruses (CoVs) target similar cell types across different human tissues and explain the presence of similar clinical features in patients infected with different CoVs. In another case, it was shown that DPP4 acted for CoV co-receptor, thus suggesting a potential similar mechanism of entry for SARS-CoV-2 [5] .	./cache/cord-306826-vbfdxoc2.txt	./txt/cord-306826-vbfdxoc2.txt